197 related articles for article (PubMed ID: 27958657)
1. Utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
Wang L; Chen W; Xi W; Feng J; Dang P; Ma Y; Yu Y
J Med Virol; 2017 Jul; 89(7):1235-1240. PubMed ID: 27958657
[TBL] [Abstract][Full Text] [Related]
2. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
[TBL] [Abstract][Full Text] [Related]
3. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.
Tedder RS; Tuke P; Wallis N; Wright M; Nicholson L; Grant PR
J Viral Hepat; 2013 Jan; 20(1):65-71. PubMed ID: 23231086
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy.
Maynard M; Pradat P; Berthillon P; Picchio G; Voirin N; Martinot M; Marcellin P; Trepo C
J Viral Hepat; 2003 Jul; 10(4):318-23. PubMed ID: 12823600
[TBL] [Abstract][Full Text] [Related]
5. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F
J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
[TBL] [Abstract][Full Text] [Related]
7. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy.
Soffredini R; Rumi MG; Parravicini ML; Ronchi G; Del Ninno E; Russo A; Colombo M
Am J Gastroenterol; 2004 Sep; 99(9):1738-43. PubMed ID: 15330912
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection.
Garbuglia AR; Lionetti R; Lapa D; Taibi C; Visco-Comandini U; Montalbano M; D'Offizi G; Castiglione F; Capobianchi MR; Paci P
J Clin Virol; 2015 Aug; 69():68-73. PubMed ID: 26209382
[TBL] [Abstract][Full Text] [Related]
10. [Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
Higashimoto M; Takahashi M; Jokyu R; Saito H
Rinsho Byori; 2006 Feb; 54(2):111-5. PubMed ID: 16548229
[TBL] [Abstract][Full Text] [Related]
11. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL
J Clin Virol; 2017 Jul; 92():32-38. PubMed ID: 28521211
[TBL] [Abstract][Full Text] [Related]
13. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
[TBL] [Abstract][Full Text] [Related]
14. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.
Pradat P; Maynard M; Buti M; Berthillon P; Picchio G; Tillmann HL; Wiegand J; Voirin N; Manns MP; Esteban JI; Martinot M; Marcellin P; Trepo C
J Med Virol; 2004 Jul; 73(3):392-6. PubMed ID: 15170634
[TBL] [Abstract][Full Text] [Related]
16. Utility of HCV core antigen ELISA in the screening for hepatitis C virus infection in patients on hemodialysis.
Reddy AK; Dakshinamurty KV; Lakshmi V
Indian J Med Microbiol; 2006 Jan; 24(1):55-7. PubMed ID: 16505558
[TBL] [Abstract][Full Text] [Related]
17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus core antigen assay: an alternative method for hepatitis C diagnosis.
Wang L; Lv H; Zhang G
Ann Clin Biochem; 2017 Mar; 54(2):279-285. PubMed ID: 27614354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]